Find the best therapeutic path
OPM’s culture is based on sharing, mutual assistance, community, sociability, and, more generally, solidarity.
OPM is a biopharmaceutical company specialized in precision medicine.
On 1 July 2022, Oncodesign announced the spin-off and transfer of its Biotech activity including AI to Oncodesign Precision Medicine (OPM).
With its diversified portfolio of technologies, molecules, and therapeutic targets, OPM has well and truly established its ability to discover active molecules for use against resistant and advanced cancers.
An innovative platform for selecting new therapeutic targets has been developed based on data obtained from patients and through an innovative approach using artificial intelligence (AI).
OPM currently has two kinase inhibitors in clinical trials:
OPM-101, for the treatment of chronic immuno-inflammatory digestive diseases and immuno-oncology, demonstrated high target engagement and absence of toxicity in its phase I trial in healthy volunteers. Phase Ib/IIa is scheduled to start at the beginning of 2025.
OPM-201, initially licensed out to Servier
for the treatment of Parkinson’s disease, completed its Phase I trial in healthy volunteers this year and returned to the OPM portfolio.
Finally, a third kinase inhibitor, OPM-102, targeting oncology, is in preclinical development.
These three molecules come from the Nanocyclix® technology platform, which enables the design and selection of small macrocyclic kinase inhibitors that are highly effective and selective.
Today, we have 12,000 molecules in our library and will be using AI to accelerate the discovery of drug candidates while reducing the cost of this phase.
OPM’s two other technology platforms are:
(i) OncoSNIPER, for the selection of therapeutic targets using artificial intelligence, in partnership with Servier for the search of targets in pancreatic cancer,
(ii) PROMETHE® for the design and selection of radiolabeled biological molecules for systemic radiotherapy, for which we have signed a partnership agreement with Navigo and are currently discussing partnerships with other
vectorization companies.
Life is constantly adapting to new conditions. It innovates to keep going. We use our intelligence to move towards success.
